PARP inhibitors target ATM+p53-defective gastric cancer

Saved in:
Bibliographic Details
Published inCell cycle (Georgetown, Tex.) Vol. 13; no. 20; pp. 3161 - 3162
Main Author Curtin, Nicola J
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 15.10.2014
Subjects
Antineoplastic Agents - pharmacology
Apoptosis - drug effects
Ataxia Telangiectasia Mutated Proteins - genetics
Cell Cycle & Views
Humans
Phthalazines - pharmacology
Piperazines - pharmacology
Poly(ADP-ribose) Polymerase Inhibitors
Stomach Neoplasms - pathology
Tumor Suppressor Protein p53 - metabolism
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Commentary-3
content type line 23
Comment on: Kubota E, et al. Cell Cycle 2014; 13(13):2129-137; PMID:24841718; http://dx.doi.org/10.4161/cc.29212
ISSN:1538-4101
1551-4005
DOI:10.4161/15384101.2014.948787